FDA Licenses Blood Product to Prevent Joint Damage in Children with Hemophilia A
The U.S. Food and Drug Administration today
approved a new use for the blood product Kogenate FS to reduce the frequency of
bleeding episodes and prevent joint damage in children with the most severe
form of hemophilia.